Darunavir concentration in PBMCs may be a better indicator of drug exposure in HIV patients

Eur J Clin Pharmacol. 2018 Aug;74(8):1055-1060. doi: 10.1007/s00228-018-2464-y. Epub 2018 May 2.

Abstract

Purpose: The clinical efficacies of some antiretroviral drugs are known to not depend on its concentration in blood. To establish a method of dosage adjustment for darunavir (DRV) based on pharmacokinetic theory, we analyzed the correlation between DRV levels in peripheral blood mononuclear cells (PBMCs) and plasma.

Methods: The concentrations of DRV and ritonavir (RTV) in plasma and PBMCs of 31 samples obtained from 19 patients were analyzed. An in vitro kinetic study using MOLT-4 cells was performed to assess the contribution of RTV to the intracellular accumulation of DRV.

Results: DRV levels in PBMCs varied between 7.91 and 29.36 ng/106 cells (CV 37.5%), while those in plasma were greater. No significant correlation was found between the trough level of DRV in plasma and that in PBMCs (p = 0.575). The inter-day difference in DRV levels in PBMCs seemed smaller than that in plasma (- 41.6-23.0% vs - 83.3-109.1%). In the in vitro study, the elimination half-life of cellular efflux of DRV was 15.7 h in the absence of RTV and extended to 47.6 h in the presence of RTV.

Conclusions: We found a poor correlation between intracellular DRV and plasma DRV levels in patients receiving highly active antiretroviral therapy. The efflux rate of DRV from cells was slow; therefore, the concentration of DRV in PBMCs may reflect average exposure to the drug and clinical efficacy.

Keywords: Darunavir; Efflux; Intracellular; PBMC; Ritonavir.

Publication types

  • Clinical Trial

MeSH terms

  • Cell Line, Tumor
  • Darunavir / administration & dosage*
  • Darunavir / blood*
  • Darunavir / pharmacokinetics
  • Drug Interactions
  • Female
  • HIV Infections / blood*
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / blood
  • HIV Protease Inhibitors / pharmacokinetics
  • HIV Protease Inhibitors / pharmacology
  • Humans
  • Leukocytes, Mononuclear / metabolism*
  • Male
  • Middle Aged
  • Ritonavir / blood
  • Ritonavir / pharmacokinetics
  • Ritonavir / pharmacology

Substances

  • HIV Protease Inhibitors
  • Ritonavir
  • Darunavir